Computational design of binding proteins to EGFR domain II

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Choi, Yoon Sup ^a,b,e   Yoon, Soomin ^a   Kim, Kyung Lock ^b   Yoo, Jiho ^c   Song, Parkyong ^b   Kim, Minsoo ^a,d   Shin, Young Eun ^b   Yang, Won Jun ^a   Noh, Jung Eun ^b   Cho, Hyun Soo ^c   Kim, Sanguk ^b   Chung, Junho ^a   Ryu, Sung Ho ^b  

^a Seoul National University College of Medicine   (South Korea)

^b Pohang University of Science and Technology (POSTECH)   (South Korea)

^c Yonsei University   (South Korea)

^d Scripps Korea Antibody Institute   (South Korea)

^e KT Convergence BU   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEOME; EGFR PROTEIN, HUMAN; PEPTIDE LIBRARY; PROTEIN BINDING;

ARTICLE; CONTROLLED STUDY; DIMERIZATION; DIRECTED MOLECULAR EVOLUTION; HUMAN; PHAGE DISPLAY; PROCESS DEVELOPMENT; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; CHEMISTRY; COMPUTER SIMULATION; DRUG DESIGN; PEPTIDE LIBRARY; PROTEIN TERTIARY STRUCTURE;

COMPUTER SIMULATION; DRUG DESIGN; HUMANS; PEPTIDE LIBRARY; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84899419835     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0092513     Document Type: Article

References (47)

1. Yamada T, Bork P (2009) Evolution of biomolecular networks: lessons from metabolic and protein interactions. Nat Rev Mol Cell Biol 10: 791-803.
2. Berg J, Lassig M, Wagner A (2004) Structure and evolution of protein interaction networks: a statistical model for link dynamics and gene duplications. BMC Evol Biol 4: 51.
3. Levy ED, Pereira-Leal JB (2008) Evolution and dynamics of protein interactions and networks. Curr Opin Struct Biol 18: 349-357.
4. Wagner A (2003) How the global structure of protein interaction networks evolves. Proc Biol Sci 270: 457-466.
5. Kim PM, Lu LJ, Xia Y, Gerstein MB (2006) Relating three-dimensional structures to protein networks provides evolutionary insights. Science 314: 1938-1941. (Pubitemid 46026118)
6. van Noort V, Snel B, Huynen MA (2004) The yeast coexpression network has a small-world, scale-free architecture and can be explained by a simple model. EMBO Rep 5: 280-284. (Pubitemid 38500108)
7. Binz HK, Amstutz P, Pluckthun A (2005) Engineering novel binding proteins from nonimmunoglobulin domains. Nat Biotechnol 23: 1257-1268. (Pubitemid 41486853)
8. Skerra A (2007) Alternative non-antibody scaffolds for molecular recognition. Curr Opin Biotechnol 18: 295-304.
9. Gebauer M, Skerra A (2009) Engineered protein scaffolds as next-generation antibody therapeutics. Curr Opin Chem Biol 13: 245-255.
10. Koide A, Bailey CW, Huang X, Koide S (1998) The fibronectin type III domain as a scaffold for novel binding proteins. J Mol Biol 284: 1141-1151. (Pubitemid 28558562)
11. Xu L, Aha P, Gu K, Kuimelis RG, Kurz M, et al. (2002) Directed evolution of high-affinity antibody mimics using mRNA display. Chem Biol 9: 933-942. (Pubitemid 35240913)
12. Getmanova EV, Chen Y, Bloom L, Gokemeijer J, Shamah S, et al. (2006) Antagonists to human and mouse vascular endothelial growth factor receptor 2 generated by directed protein evolution in vitro. Chem Biol 13: 549-556. (Pubitemid 43744513)
13. Tolcher AW, Sweeney CJ, Papadopoulos K, Patnaik A, Chiorean EG, et al. (2011) Phase I and pharmacokinetic study of CT-322 (BMS-844203), a targeted Adnectin inhibitor of VEGFR-2 based on a domain of human fibronectin. Clin Cancer Res 17: 363-371.
14. Schlehuber S, Skerra A (2005) Lipocalins in drug discovery: from natural ligand-binding proteins to ''anticalins''. Drug Discov Today 10: 23-33. (Pubitemid 40164816)
15. Schlehuber S, Skerra A (2005) Anticalins as an alternative to antibody technology. Expert Opin Biol Ther 5: 1453-1462. (Pubitemid 41579430)
16. Skerra A (2007) Anticalins as alternative binding proteins for therapeutic use. Curr Opin Mol Ther 9: 336-344.
17. Stumpp MT, Binz HK, Amstutz P (2008) DARPins: a new generation of protein therapeutics. Drug Discov Today 13: 695-701.
18. Stumpp MT, Amstutz P (2007) DARPins: a true alternative to antibodies. Curr Opin Drug Discov Devel 10: 153-159. (Pubitemid 46438644)
19. Binz HK, Amstutz P, Kohl A, Stumpp MT, Briand C, et al. (2004) High-affinity binders selected from designed ankyrin repeat protein libraries. Nat Biotechnol 22: 575-582. (Pubitemid 38590636)
20. Fleishman SJ, Whitehead TA, Ekiert DC, Dreyfus C, Corn JE, et al. (2011) Computational design of proteins targeting the conserved stem region of influenza hemagglutinin. Science 332: 816-821.
21. Bianco R, Gelardi T, Damiano V, Ciardiello F, Tortora G (2007) Rational bases for the development of EGFR inhibitors for cancer treatment. Int J Biochem Cell Biol 39: 1416-1431. (Pubitemid 47031050)
22. Lockhart AC (2005) The epidermal growth factor receptor as a target for colorectal cancer therapy (vol 32, pg 52, 2005). Seminars in Oncology 32: 432-432.
23. Mendelsohn J, Baselga J (2000) The EGF receptor family as targets for cancer therapy. Oncogene 19: 6550-6565. (Pubitemid 32197693)
24. Woodburn JR (1999) The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 82: 241-250.
25. Ferguson KM, Berger MB, Mendrola JM, Cho HS, Leahy DJ, et al. (2003) EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization. Mol Cell 11: 507-517. (Pubitemid 36297057)
26. Ogiso H, Ishitani R, Nureki O, Fukai S, Yamanaka M, et al. (2002) Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell 110: 775-787. (Pubitemid 35291060)
27. Li S, Schmitz KR, Jeffrey PD, Wiltzius JJ, Kussie P, et al. (2005) Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 7: 301-311. (Pubitemid 40544648)
28. Sivasubramanian A, Chao G, Pressler HM, Wittrup KD, Gray JJ (2006) Structural model of the mAb 806-EGFR complex using computational docking followed by computational and experimental mutagenesis. Structure 14: 401-414. (Pubitemid 43363474)
29. Garrett TP, Burgess AW, Gan HK, Luwor RB, Cartwright G, et al. (2009) Antibodies specifically targeting a locally misfolded region of tumor associated EGFR. Proc Natl Acad Sci U S A 106: 5082-5087.
30. Scott AM, Lee FT, Tebbutt N, Herbertson R, Gill SS, et al. (2007) A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors. Proc Natl Acad Sci U S A 104: 4071-4076. (Pubitemid 47181580)
31. Schneidman-Duhovny D, Inbar Y, Nussinov R, Wolfson HJ (2005) PatchDock and SymmDock: servers for rigid and symmetric docking. Nucleic Acids Res 33: W363-367. (Pubitemid 44529944)
32. Schneidman-Duhovny D, Inbar Y, Polak V, Shatsky M, Halperin I, et al. (2003) Taking geometry to its edge: fast unbound rigid (and hinge-bent) docking. Proteins 52: 107-112. (Pubitemid 36648858)
33. Chai J, Wu JW, Yan N, Massague J, Pavletich NP, et al. (2003) Features of a Smad3 MH1-DNA complex. Roles of water and zinc in DNA binding. J Biol Chem 278: 20327-20331. (Pubitemid 36799232)
34. Baig I, Bertini I, Del Bianco C, Gupta YK, Lee YM, et al. (2004) Paramagnetism-based refinement strategy for the solution structure of human alpha-parvalbumin. Biochemistry 43: 5562-5573. (Pubitemid 38620948)
35. Pokala N, Handel TM (2005) Energy functions for protein design: adjustment with protein-protein complex affinities, models for the unfolded state, and negative design of solubility and specificity. J Mol Biol 347: 203-227. (Pubitemid 40283639)
36. Sheriff S, Silverton EW, Padlan EA, Cohen GH, Smith-Gill SJ, et al. (1987) Three-dimensional structure of an antibody-antigen complex. Proc Natl Acad Sci U S A 84: 8075-8079.
37. Cohen GH, Silverton EW, Padlan EA, Dyda F, Wibbenmeyer JA, et al. (2005) Water molecules in the antibody-antigen interface of the structure of the Fab HyHEL-5-lysozyme complex at 1.7 A resolution: comparison with results from isothermal titration calorimetry. Acta Crystallogr D Biol Crystallogr 61: 628-633. (Pubitemid 44336735)
38. Ladner RC (2007) Mapping the epitopes of antibodies. Biotechnol Genet Eng Rev 24: 1-30.
39. Lo Conte L, Ailey B, Hubbard TJ, Brenner SE, Murzin AG, et al. (2000) SCOP: a structural classification of proteins database. Nucleic Acids Res 28: 257-259. (Pubitemid 30047773)
40. Tusnady GE, Dosztanyi Z, Simon I (2005) PDB-TM: selection and membrane localization of transmembrane proteins in the protein data bank. Nucleic Acids Res 33: D275-278. (Pubitemid 40207877)
41. Tusnady GE, Dosztanyi Z, Simon I (2004) Transmembrane proteins in the Protein Data Bank: identification and classification. Bioinformatics 20: 2964-2972. (Pubitemid 39619188)
42. Sussman JL, Lin D, Jiang J, Manning NO, Prilusky J, et al. (1998) Protein Data Bank (PDB): database of three-dimensional structural information of biological macromolecules. Acta Crystallogr D Biol Crystallogr 54: 1078-1084. (Pubitemid 29000162)
43. Goel R, Muthusamy B, Pandey A, Prasad TS (2011) Human protein reference database and human proteinpedia as discovery resources for molecular biotechnology. Mol Biotechnol 48: 87-95.
44. Bairoch A, Boeckmann B, Ferro S, Gasteiger E (2004) Swiss-Prot: juggling between evolution and stability. Brief Bioinform 5: 39-55.
45. Choi YS, Yang JS, Choi Y, Ryu SH, Kim S (2009) Evolutionary conservation in multiple faces of protein interaction. Proteins 77: 14-25.
46. Choi YS, Han SK, Kim J, Yang JS, Jeon J, et al. (2010) ConPlex: a server for the evolutionary conservation analysis of protein complex structures. Nucleic Acids Res 38: W450-456.
47. Hubbard SJ, Thornton JM (1993) NACCESS. Computer Program, University College, London.